Compare AbbVie Inc (ABBV) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Exxon Mobil Corporation — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Exxon Mobil Corporation trades at $141.48 (market cap $587.30B). The key difference: Exxon Mobil Corporation is the larger of the two by market cap, and Exxon Mobil Corporation pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| ABBV | XOM | |
|---|---|---|
Market Cap | $449.91B | $587.30B |
Sector | Health | Energy |
52-Week High | $261.07 | $171.52 |
52-Week Low | $184.85 | $105.83 |
Enterprise Value | $513.38B | $626.52B |
Dividend Yield | 2.72% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
ExxonMobil (XOM) trades at $136.44, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong operational cash flow of $52.0B in 2025 and a healthy balance sheet with 15.44% debt-to-capitalization. Recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $150-160 per barrel amid Middle East tensions.
XOM presents a mixed outlook with attractive valuation metrics (P/E 22.97, below energy sector average) and analyst consensus target of $172.79 (26% upside). However, declining revenue trends ($323.9B in 2025 vs. $398.7B in 2022) and bearish technical indicators suggest near-term headwinds. The stock offers income potential with recent $1.03 dividend but faces oil price volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
